Fig. 3. Further improvement of KRasG12C inhibitors. a, Chemical structures of compound 12Ostrem (5), ARS-107 (6), ARS-853 (7) and ARS-1620 (8). b, Biochemical and cellular data as well as drug-like properties of compounds shown in Fig. 2a. c, Co-crystal structure of KRasG12C in the GDP state bound to compound ARS-853 (7) (left, pdb id ; 5f2e) and key interactions (right). d, Co-crystal structure of KRasG12C in the GDP state bound to compound ARS-1620 (8) (left, pdb id ; 5v9u) and key interactions (right).
